It's important to understand that when treating AML patients with the currently approved drugs, including VYXEOS Celator's lead drug, which is now owned by Jazz Pharmaceuticals after their acquisition of Celator , cardiotoxicity is the number one dose limiting toxicity for oncologists. Show all 1 star and higher - 2 2 stars and higher - 2 3 stars and higher - 2 4 stars and higher - 2. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing...
Read more